Literature DB >> 7634441

Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty.

M Hamon1, C Bauters, C Amant, E P McFadden, N Helbecque, J M Lablanche, M E Bertrand, P Amouyel.   

Abstract

BACKGROUND: The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has been implicated in the pathogenesis of coronary artery disease. The deletion allele is strongly associated with the level of circulating ACE and is a potent risk factor for myocardial infarction. Recently, the deletion allele was also associated with the occurrence of visually diagnosed restenosis after percutaneous transluminal coronary angioplasty (PTCA) in a selected population of patients with acute myocardial infarction. METHODS AND
RESULTS: We investigated the influence of the ACE I/D polymorphism on the occurrence of restenosis after PTCA with the use of quantitative coronary angiography. ACE I/D genotypes were characterized in 118 consecutive patients who had one-vessel disease and were undergoing systematic angiographic follow-up. Coronary angiograms were analyzed before and after PTCA and at follow-up (7.4 +/- 3.0 months). Before PTCA, there were no clinical or angiographic differences among the three groups of genotypes (DD, n = 39; ID, n = 62; II, n = 17). After PTCA, the mean differences in minimal luminal diameter between post-PTCA and pre-PTCA angiograms (acute gain) were identical in the three groups, as was the mean percent residual stenosis. At follow-up angiography, the mean difference in minimal coronary luminal diameter between post-PTCA and follow-up angiograms (late loss) was not significantly different in the three groups of genotypes. The percentage of patients with restenosis defined as a > 50% stenosis was identical in the three groups.
CONCLUSIONS: In this quantitative study, the I/D polymorphism of the ACE gene had no influence on the occurrence of restenosis after coronary angioplasty.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634441     DOI: 10.1161/01.cir.92.3.296

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries.

Authors:  M Hamon; C Amant; C Bauters; F Richard; N Helbecque; E McFadden; J M Lablanche; M Bertrand; P Amouyel
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 2.  Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction.

Authors:  Timmy Lee; Davinder Wadehra
Journal:  Semin Dial       Date:  2011-09-15       Impact factor: 3.455

Review 3.  Genetic risk factors and restenosis after percutaneous coronary interventions.

Authors:  A Kastrati; J Dirschinger; A Schömig
Journal:  Herz       Date:  2000-02       Impact factor: 1.443

4.  Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention.

Authors:  M Hamon; S Fradin; A Denizet; E Filippi-Codaccioni; G Grollier; R Morello
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

Review 5.  Angiotensin-converting enzyme inhibitors and coronary artery disease.

Authors:  J W Sayer; A D Timmis
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

Review 6.  Pharmacological approaches to the prevention of restenosis after coronary angioplasty.

Authors:  M Hamon; E Lécluse; J P Monassier; G Grollier; J C Potier
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

Review 7.  [Genetic risk factors for myocardial infarct].

Authors:  D H Walter; A M Zeiher
Journal:  Herz       Date:  2000-02       Impact factor: 1.740

8.  Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms.

Authors:  Nicolas Lamblin; Xavier Hermant; Jean-Marc Lablanche; Nicole Helbecque; Philippe Amouyel; Christophe Bauters
Journal:  Thromb J       Date:  2003-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.